Results 231 to 240 of about 32,908 (264)
Some of the next articles are maybe not open access.

Dual antiplatelet therapy escalation and de-escalation

European Heart Journal: Acute Cardiovascular Care
Abstract Dual antiplatelet therapy (DAPT) remains a key element of secondary prevention after percutaneous coronary intervention. However, its optimal duration and intensity continue to pose challenges due to the trade-off between ischaemic protection and bleeding risk.
Antonio Greco   +4 more
openaire   +2 more sources

A safer bet for MitraClip: Choosing between single antiplatelet therapy and dual antiplatelet therapy

International Journal of Cardiology
Optimal antithrombotic therapy after mitral valve transcatheter edge-to-edge repair (TEER) remains uncertain.To compare the efficacy and safety of single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) in mitral TEER recipients.We retrospectively queried the TriNetX Global Network, identifying 3325 adult patients who underwent ...
Yaman, Jarrar   +7 more
openaire   +2 more sources

Dual Antiplatelet Therapy

JAMA, 2019
Khaled M, Ziada, David J, Moliterno
openaire   +2 more sources

[New antiplatelet agents and the question of dual antiplatelet therapy].

Der Internist, 2012
The introduction of clopidogrel for use with aspirin (ASA) as a dual antiplatelet therapy has markedly reduced the risk of atherothrombotic vessel occlusion in patients with acute coronary syndromes (ACS). However, stronger antiplatelet therapy has also been associated with significant increases in severe bleeding, resulting in no change in mortality ...
openaire   +1 more source

Dual antiplatelet therapy duration and mortality

The Lancet, 2015
Johann, Auer   +2 more
openaire   +2 more sources

Effects of dual antiplatelet therapy on graft patency after lower extremity bypass

Journal of Vascular Surgery, 2021
Jordan B Stoecker   +2 more
exaly  

Home - About - Disclaimer - Privacy